Summary of Study ST001836

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001157. The data can be accessed directly via it's Project DOI: 10.21228/M8510S This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001836
Study TitleQuantitative lipids study on blood serum and ceacal content of rat models
Study Typeblood serum and caecum content
Study SummaryLipids were analyzed in blood serum and cecal content in rat models
Institute
Helmholtz Centre for Environmental Research
DepartmentDepartment of Molecular Systems biology
LaboratoryFunctional Metabolomics
Last NameRolle-Kampczyk
First NameUlrike
AddressPermoserstrasse 15, 04318 Leipzig, Germany
Emailulrike.rolle-kampczyk@ufz.de
Phone0049 341 235 1537
Submit Date2021-06-21
Raw Data AvailableYes
Raw Data File Type(s)wiff
Analysis Type DetailLC-MS
Release Date2021-07-02
Release Version1
Ulrike Rolle-Kampczyk Ulrike Rolle-Kampczyk
https://dx.doi.org/10.21228/M8510S
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001157
Project DOI:doi: 10.21228/M8510S
Project Title:Fecal Transplant from Roux-Y-Gastric-Bypass rat model into a diet induced obesity rat model
Project Summary:Investigating alterations in the intestinal microbiome metabolome and host blood metabolome in a diet induced obesity (DIO) rat model after fecal transplant from rats, which underwent Roux-Y-Gastric-Bypass surgery (RYGB). Experimental groups for rat experiments. 1)Rats in the ‘RYGB_Donor group’ underwent RYGB surgery. Postoperatively, animals received a two-choice diet, consisting of a SC and HFD. Once the animals recovered and achieved a stabilized weight reduction at 4 weeks postoperatively, body weight and food intake were recorded daily. 2)Rats allocated into the ‘RYGB_AB group’ were handled the same as animals in the ‘RYGB_donor group’. From postoperative week 4 onwards, animals received an antibiotic treatment (AB) consisting of ampicillin (1 g/l; Ratiopharm), vancomycin (0.5 g/l; Ratiopharm), neomycin (1 g/l; Bela-pharm), and metronidazole (1 g/l; CP-Pharma), provided freshly every day via drinking water.[19, 20] All antibiotics were given for the time period indicated in each figure.[21] 3)Rats in the ‘Lean group’ served as healthy, age-matched controls, constantly kept under SC. 4)Rats in the ‘Lean_AB group’ received the same antibiotic treatment as animals in the RYGB_AB group, serving as a control for antibiotic-specific side effects. All antibiotics were given for the time periods indicated in each figure. 5)Rats in the ‘DIO group’ received no surgery, but were otherwise handled like RYGB litter mates. 6)Rats in the ‘DIO_FMT_RYGB group’ received fecal RYGB_Donor microbiota transplantation once per week, but were otherwise handled like DIO litter mates. For fecal transplantation experiments, 100 mg of fresh stool from body weight-stabilized RYGB donors were re-suspended in 1 ml of PBS, homogenized carefully and administered via oral gavage with 200 μl of the suspension. 7)Rats in the ‘FMT_Lean group’ were handled like DIO litter mates, but were orally gavaged with 200 μl of filtrate received from lean donors, and served as a control for fecal transplantation and specificity of effect size(s) as a function of the donor microbiota. 8)Rats in the ‘DIO_PF_FMT group’ were handled like DIO litter mates, but pair-fed to the SC/HFD food intake of ‘FMT_Lean littermates, serving as a control for effects secondary to reduced caloric intake.
Institute:Helmholtz Centre for Environmental Research - UFZ
Last Name:Haange
First Name:Sven
Address:Permoserstrasse 1, Leipzig, Saxony, 04318, Germany
Email:sven.haange@ufz.de
Phone:0049 341 2351099

Subject:

Subject ID:SU001913
Subject Type:Mammal
Subject Species:Rattus norvegicus
Taxonomy ID:10116

Factors:

Subject type: Mammal; Subject species: Rattus norvegicus (Factor headings shown in green)

mb_sample_id local_sample_id Tissue
SA1706861024038893Caecum | Sample treatment:DIO
SA1706871024038904Caecum | Sample treatment:DIO
SA1706881024041219Caecum | Sample treatment:DIO
SA1706891024038919Caecum | Sample treatment:DIO
SA1706901024038651Caecum | Sample treatment:DIO
SA1706911024038923Caecum | Sample treatment:DIO
SA1706921024041363Caecum | Sample treatment:DIO
SA1706931024041378Caecum | Sample treatment:DIO
SA1706941024041295Caecum | Sample treatment:DIO
SA1706951024041276Caecum | Sample treatment:DIO
SA1706961024035756Caecum | Sample treatment:DIO_AB
SA1706971024035775Caecum | Sample treatment:DIO_AB
SA1706981024041223Caecum | Sample treatment:DIO_AB
SA1706991024041261Caecum | Sample treatment:DIO_AB
SA1707001024041238Caecum | Sample treatment:DIO_AB
SA1707011024041242Caecum | Sample treatment:DIO_AB
SA1707021024041382Caecum | Sample treatment:DIO_FMT_RYGB
SA1707031024041325Caecum | Sample treatment:DIO_FMT_RYGB
SA1707041024038671Caecum | Sample treatment:DIO_FMT_RYGB
SA1707051024038860Caecum | Sample treatment:DIO_FMT_RYGB
SA1707061024038841Caecum | Sample treatment:DIO_FMT_RYGB
SA1707071024038666Caecum | Sample treatment:DIO_FMT_RYGB
SA1707081024041257Caecum | Sample treatment:DIO_FMT_RYGB
SA1707091024038874Caecum | Sample treatment:DIO_FMT_RYGB
SA1707101024041281Caecum | Sample treatment:DIO_FMT_RYGB
SA1707111024038889Caecum | Sample treatment:DIO_FMT_RYGB
SA1707121024038938Caecum | Sample treatment:DIO_PF_FMT
SA1707131024038942Caecum | Sample treatment:DIO_PF_FMT
SA1707141024038981Caecum | Sample treatment:DIO_PF_FMT
SA1707151024038957Caecum | Sample treatment:DIO_PF_FMT
SA1707161024038961Caecum | Sample treatment:DIO_PF_FMT
SA1707171024038976Caecum | Sample treatment:DIO_PF_FMT
SA1707181024041408Caecum | Sample treatment:FMT_lean
SA1707191024041397Caecum | Sample treatment:FMT_lean
SA1707201024041330Caecum | Sample treatment:FMT_lean
SA1707211024041359Caecum | Sample treatment:FMT_lean
SA1707221024035761Caecum | Sample treatment:FMT_lean
SA1707231024041344Caecum | Sample treatment:FMT_lean
SA1707241024041311Caecum | Sample treatment:Lean
SA1707251024038995Caecum | Sample treatment:Lean
SA1707261024039011Caecum | Sample treatment:Lean
SA1707271024039007Caecum | Sample treatment:Lean
SA1707281024041306Caecum | Sample treatment:Lean
SA1707291024038753Caecum | Sample treatment:Lean
SA1707301024038802Caecum | Sample treatment:Lean
SA1707311024039026Caecum | Sample treatment:Lean
SA1707321024038768Caecum | Sample treatment:Lean
SA1707331024038791Caecum | Sample treatment:Lean
SA1707341024032782Caecum | Sample treatment:Lean_AB
SA1707351024032797Caecum | Sample treatment:Lean_AB
SA1707361024038787Caecum | Sample treatment:Lean_AB
SA1707371024038772Caecum | Sample treatment:Lean_AB
SA1707381024038734Caecum | Sample treatment:Lean_AB
SA1707391024038749Caecum | Sample treatment:Lean_AB
SA1707401024041465Caecum | Sample treatment:RYGB_AB
SA1707411024041446Caecum | Sample treatment:RYGB_AB
SA1707421024041484Caecum | Sample treatment:RYGB_AB
SA1707431024032778Caecum | Sample treatment:RYGB_AB
SA1707441024038690Caecum | Sample treatment:RYGB_AB
SA1707451024032763Caecum | Sample treatment:RYGB_AB
SA1707461024038685Caecum | Sample treatment:RYGB_AB
SA1707471024038720Caecum | Sample treatment:RYGB_AB
SA1707481024032759Caecum | Sample treatment:RYGB_AB
SA1707491024041427Caecum | Sample treatment:RYGB_Donor
SA1707501024041431Caecum | Sample treatment:RYGB_Donor
SA1707511024038836Caecum | Sample treatment:RYGB_Donor
SA1707521024041412Caecum | Sample treatment:RYGB_Donor
SA1707531024032744Caecum | Sample treatment:RYGB_Donor
SA1707541024041451Caecum | Sample treatment:RYGB_Donor
SA1707551024038701Caecum | Sample treatment:RYGB_Donor
SA1707561024038715Caecum | Sample treatment:RYGB_Donor
SA1707571024038821Caecum | Sample treatment:RYGB_Donor
SA1707581024033074Plasma | Sample treatment:DIO
SA1707591024033093Plasma | Sample treatment:DIO
SA1707601024033060Plasma | Sample treatment:DIO
SA1707611024033089Plasma | Sample treatment:DIO
SA1707621024033036Plasma | Sample treatment:DIO_FMT_RYGB
SA1707631024033041Plasma | Sample treatment:DIO_FMT_RYGB
SA1707641024033055Plasma | Sample treatment:DIO_FMT_RYGB
SA1707651024033021Plasma | Sample treatment:DIO_FMT_RYGB
SA1707661024033104Plasma | Sample treatment:DIO_PF_FMT
SA1707671024033119Plasma | Sample treatment:DIO_PF_FMT
SA1707681024035794Plasma | Sample treatment:DIO_PF_FMT
SA1707691024035780Plasma | Sample treatment:DIO_PF_FMT
SA1707701024035805Plasma | Sample treatment:DIO_PF_FMT
SA1707711024035810Plasma | Sample treatment:DIO_PF_FMT
SA1707721024035843Plasma | Sample treatment:Lean
SA1707731024035858Plasma | Sample treatment:Lean
SA1707741024035824Plasma | Sample treatment:Lean
SA1707751024035839Plasma | Sample treatment:Lean
SA1707761024032971Plasma | Sample treatment:RYGB_AB
SA1707771024033017Plasma | Sample treatment:RYGB_AB
SA1707781024032991Plasma | Sample treatment:RYGB_AB
SA1707791024032952Plasma | Sample treatment:RYGB_Donor
SA1707801024032933Plasma | Sample treatment:RYGB_Donor
SA1707811024032948Plasma | Sample treatment:RYGB_Donor
SA1707821024032986Plasma | Sample treatment:RYGB_Donor
SA1707831024032638Serum | Sample treatment:DIO
SA1707841024032623Serum | Sample treatment:DIO
SA1707851024041174Serum | Sample treatment:DIO
Showing page 1 of 2     Results:    1  2  Next     Showing results 1 to 100 of 143

Collection:

Collection ID:CO001906
Collection Summary:Animals were sacrificed, blood and cecum tissue were removed, snap frozen in liquid nitrogen and stored at -80°C until further analysis
Sample Type:Cecum

Treatment:

Treatment ID:TR001926
Treatment Summary:RYGB surgery was performed on age-matched (8-10-weeks old) male Wistar IGS rats. After four weeks of recovery, animals were put on an antibiotic cocktail consisting of ampicillin (1 g/l; Ratiopharm), vancomycin (0.5 g/l; Ratiopharm), neomycin (1 g/l; Bela-pharm), and metronidazole (1 g/l; CP-Pharma), provided freshly every day via drinking water. The parallel FMT group received fecal RYGB microbiota transplantation once per week, but were otherwise handled like DIO littermates. For fecal transplantation experiments, 100 mg of fresh stool from bodyweight-stabilized RYGB donors was re-suspended in 1 ml of PBS, homogenized carefully and administered via oral gavage with 200 μl of the suspension.

Sample Preparation:

Sampleprep ID:SP001919
Sampleprep Summary:Sample preparation for MetIDQ p180 Kit measurement Solvents: Acetonitril (Merck KGaA, Darmstadt, Germany hypergrade for LC-MS) Water MiliQ, Extracting agent - ACN / H2O (1:1) Equipment 4 steel balls size M Eppendorf Tubes 2mL Tissue slicer (Rettberg, Germany) Centrifuge (Sigma) Work steps Approximately 100mg of caecum sample and 4 steel balls of size M into each tube. Per mg of sample 5µL of extracting agent was added. Shake the samples for 10 minutes at 30 Hz in the tissue slicer and centrifuge for 2 minutes at 14000 rpm. 10 µL supernatant was used for the targeted analytics. Blood serum samples 10 µL were used for analysis Kit reparation The analysis was performed using the validated MetIDQ p180 Kit and described in Siskos et al. [1]. Data processing was carried out with the provided quantitation method Kit (Biocrates Life Sciences AG, Innsbruck, Austria). 1 Siskos AP, Jain P, Römisch-Margl W, Bennett M, Achaintre D, Asad Y, et al. Interlaboratory Reproducibility of a Targeted Metabolomics Platform for Analysis of Human Serum and Plasma. Anal Chem 2017;89:656-65.

Combined analysis:

Analysis ID AN002978
Analysis type MS
Chromatography type Reversed phase
Chromatography system UPLC (Waters Acquity, Waters Corporation, Milford, USA)
Column Agilent Zorbax Eclipse XDB C18 (100 x 3.0mm,3.5um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name ABI Sciex 5500 QTrap
Ion Mode POSITIVE
Units µM

Chromatography:

Chromatography ID:CH002207
Chromatography Summary:LC - Instrument Parameters AbsoluteIDQ® p180 Kit (Biocrates Life Science AG, Innsbruck, Austria) System: UPLC (Waters Acquity, Waters Corporation, Milford, USA) Column: Agilent, Zorbax Eclipse XDB C18, 3.0 x 100 mm, 3.5 μM, Agilent Waldbronn, Germany Precolumn: Security Guard, Phenomenex, C18, 4 x 3 mm; Phenomenex, Aschaffenburg, Germany Materials: Water MiliQ, Methanol (Merck KGaA, Darmstadt, Germany, hypergrade for LC-MS) Acetonitril (Merck KGaA, Darmstadt, Germany hypergrade for LC-MS) Ammonium Acetate (Honeywell - Fluka, Seelze, Germany) Formic Acid (Honeywell, Fluka, Seelze, Germany) Running Solvent: 5mM ammonium acetat in methanol LC: A: 2mL Formic acid in MilliQ water B: 1mL Formic Acid in Acetonitrile Gradient Table LC Time (min) Flow Rate (mL/min) %A %B Curve Initial 0.500 100.0 0.0 Initial 0.50 0.500 100.0 0.0 6 4.00 0.500 30.0 70.0 6 5.30 0.500 30.0 70.0 6 5.40 0.500 100.0 0.0 6 7.30 0.500 100.0 0.0 6
Methods Filename:LC_parameters-metabolites.pdf
Instrument Name:UPLC (Waters Acquity, Waters Corporation, Milford, USA)
Column Name:Agilent Zorbax Eclipse XDB C18 (100 x 3.0mm,3.5um)
Flow Gradient:FIA Time (min) Flow Rate (mL/min) %A %B Curve Initial 0.030 0.0 100.0 Initial 1.60 0.030 0.0 100.0 6 2.40 0.200 0.0 100.0 6 2.80 0.200 0.0 100.0 6 3.00 0.030 0.0 100.0 6
Flow Rate:0.03ml/min
Solvent A:100% methanol; 5mM ammonium acetate
Solvent B:50% methanol/50% water; 5mM ammonium acetate
Chromatography Type:Reversed phase

MS:

MS ID:MS002768
Analysis ID:AN002978
Instrument Name:ABI Sciex 5500 QTrap
Instrument Type:Triple quadrupole
MS Type:ESI
MS Comments:Analyst version 1.6 Software from SCIEX. For Validation METIDQ Software version Boron from Biocrates
Ion Mode:POSITIVE
Analysis Protocol File:MS_parameters_1.pdf
  logo